Clinical Trial Detail

NCT ID NCT01619774
Title An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST